Why Exelixis, Inc. (EXEL) stock moved
Exelixis, Inc. (EXEL) shares fell 2.1% to $52.96 as of August 10, 2026, a modest decline from the prior close of $54.07. BestStocks flagged the session as a major change for EXEL. Below, we break down what changed for EXEL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
EXEL fell 2.1% to $52.96
Exelixis shares fell 5.04% to $53.15, driven by profit-taking following a strong 26.8% three-month rally and lingering concerns over FDA review timelines and mixed clinical data for pipeline drug zanzalintinib (per web analysis citing STELLAR trial results). Volume at 1.04M shares runs near normal levels for this point in the session. Exelixis earnings report scheduled for August 4, 2026 (consensus EPS estimate $0.86); monitor for any guidance on zanzalintinib development timeline and FDA feedback.
What it means for Exelixis, Inc. investors
For Exelixis, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Exelixis, Inc. (EXEL) moved +2.60% from $52.70 to $54.07 on 2026-08-07; Exelixis, Inc. (EXEL) moved +1.76% from $56.11 to $57.10 on 2026-07-09, reaching a new 30-day high. Weighing against that: Material negative event; Negative session, down 2.1%. Wall Street's consensus price target sits at $50.67, implying -4.3% downside from $52.96. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality low (44/100). With earnings roughly 85 days out, the next report is the most likely near-term test of the move.
EXEL price reaction
EXEL last traded at $52.96, down $1.11 (-2.05%) from the previous close of $54.07. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $52.20 and $56.70, and it currently sits about 17% of the way up that band.
Bullish and bearish analyst opinions on Exelixis, Inc. (EXEL)
The consensus analyst price target on Exelixis, Inc. (EXEL) is $50.67, 4.3% below the recent $52.96. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 1 downgrade. Here is how the bullish and bearish cases on EXEL line up.
The bullish case
- The Street's most bullish target is $56.00 (+5.7%).
- Exelixis, Inc. (EXEL) moved +2.60% from $52.70 to $54.07 on 2026-08-07.
The bearish case
- The consensus analyst price target of $50.67 sits 4.3% below the recent $52.96, so the average target sees limited room to run.
- The most bearish analyst target is $44.00 (-16.9%).
- 1 analyst downgrade in the past 90 days, most recently Truist Securities to Hold (2026-06-25).
- Material negative event.
- Negative session, down 2.1%.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for EXEL
Frequently asked questions about EXEL
Why did Exelixis, Inc. (EXEL) stock move?
EXEL fell 2.1% to $52.96. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did EXEL stock fall?
EXEL lost 2.05% ($1.11) versus the prior close of $54.07, last trading at $52.96 on 1.0× average volume.
When is Exelixis, Inc.'s next earnings date?
EXEL's next earnings report is estimated for 2026-11-03 — about 85 days away.
What is the analyst price target for EXEL?
The consensus analyst price target for EXEL is $50.67, about 4.3% below the current $52.96. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 1 downgrade.
How BestStocks tracks EXEL
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared EXEL-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for EXEL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.